What do you think of the CV risk cited by the FDA?
FDA seems stubborn -- "drawn a hard line on the sand" about insisting on a very large, long term CV outcome trial for Relistor. They say it is a class affect on all mu opioid antagonist. Now how is that going to affect Naloxone? All the discussion seems to center on efficacy, which I don't doubt.